A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)K. Yamazaki,Y. Kuboki,T. Nishina,E. Shinozaki,K. Shitara,W. Okamoto,T. Kajiwara,T. Matsumoto,T. Tsushima,N. Mochizuki,M. Fukutani,M. Nakamoto,Y. Hasegawa, A. Sugama,S. Nomura,A. Sato,A. Ohtsu, T. YoshinoANNALS OF ONCOLOGY（2015）引用 1|浏览16暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
